BRPI0511029A - ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase - Google Patents

ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase

Info

Publication number
BRPI0511029A
BRPI0511029A BRPI0511029-7A BRPI0511029A BRPI0511029A BR PI0511029 A BRPI0511029 A BR PI0511029A BR PI0511029 A BRPI0511029 A BR PI0511029A BR PI0511029 A BRPI0511029 A BR PI0511029A
Authority
BR
Brazil
Prior art keywords
amino
indol
pyrimidin
carbonyl
substantially pure
Prior art date
Application number
BRPI0511029-7A
Other languages
English (en)
Inventor
El-Bdaouil Haddad
Olaf Ritzeler
David Johnus Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0511029A publication Critical patent/BRPI0511029A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

áCIDO 2-{¢2-(2-METIL AMINO-PIRIMIDIN-4-IL)-1 H-INDOL-5-CARBONIL!-AMINO}-3-(FENIL PIRIDIN-2-IL-AMINO)-PROPIÈNICO SUBSTANCIALMENTE PURO COMO UM INIBIDOR DA I CAPA B QUINASE. A presente invenção refere-se ao composto substancialmente puro de acordo com a fórmula (A): ou um sal farmaceuticamente aceitável, ou solvato do dito composto; referese a uma composição farmacêutica que compreende uma quantidade farmaceuticamente eficaz do composto de acordo com a fórmula (A), e um veículo farmaceuticamente aceitável; e o uso de um composto de acordo com a fórmula (A) possuindo atividade como um inibidor, preferivelmente um inibidor seletivo, da IkB (IKK), particularmente de IKK-2, e aos métodos relacionados aos mesmos.
BRPI0511029-7A 2004-05-12 2005-05-11 ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase BRPI0511029A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12
PCT/US2005/016381 WO2005113544A1 (en) 2004-05-12 2005-05-11 Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0511029A true BRPI0511029A (pt) 2007-11-27

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511029-7A BRPI0511029A (pt) 2004-05-12 2005-05-11 ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase

Country Status (23)

Country Link
EP (1) EP1747215A1 (pt)
JP (1) JP2007537266A (pt)
KR (1) KR20070011483A (pt)
CN (1) CN1950359A (pt)
AR (1) AR049274A1 (pt)
AU (1) AU2005245834A1 (pt)
BR (1) BRPI0511029A (pt)
CA (1) CA2566213A1 (pt)
EC (1) ECSP066992A (pt)
GT (1) GT200500111A (pt)
IL (1) IL178992A0 (pt)
MA (1) MA28553B1 (pt)
MX (1) MXPA06012870A (pt)
NO (1) NO20065719L (pt)
PA (1) PA8633101A1 (pt)
PE (1) PE20060269A1 (pt)
RU (1) RU2006143758A (pt)
SV (1) SV2006002111A (pt)
TN (1) TNSN06338A1 (pt)
TW (1) TW200605881A (pt)
UY (1) UY28897A1 (pt)
WO (1) WO2005113544A1 (pt)
ZA (1) ZA200608712B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20130069641A (ko) * 2010-04-27 2013-06-26 허치슨 메디파르마 리미티드 피리미디닐 인돌 화합물
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
JP2007537266A (ja) 2007-12-20
IL178992A0 (en) 2007-03-08
ECSP066992A (es) 2006-12-29
CN1950359A (zh) 2007-04-18
RU2006143758A (ru) 2008-06-27
SV2006002111A (es) 2006-01-30
GT200500111A (es) 2006-05-09
AU2005245834A1 (en) 2005-12-01
PE20060269A1 (es) 2006-05-11
ZA200608712B (en) 2008-06-25
NO20065719L (no) 2006-12-12
TW200605881A (en) 2006-02-16
EP1747215A1 (en) 2007-01-31
AR049274A1 (es) 2006-07-12
CA2566213A1 (en) 2005-12-11
MA28553B1 (fr) 2007-04-03
PA8633101A1 (es) 2006-01-23
WO2005113544A1 (en) 2005-12-01
KR20070011483A (ko) 2007-01-24
UY28897A1 (es) 2005-12-30
MXPA06012870A (es) 2007-02-15
TNSN06338A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
BR112012007069A2 (pt) derivado de fenol
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
EA200970856A1 (ru) Ингибиторы пути хеджхога
AR061974A1 (es) Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
MX337906B (es) Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
BRPI0618362A2 (pt) sais farmacêuticos inovadores e polimorfos de um inibidor de fator xa
TNSN06338A1 (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
BR112013009935B8 (pt) Compostos
EA200970156A1 (ru) Пиридизиноновые производные
ZA200902384B (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
UY30387A1 (es) Nuevos compuestos
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
AR074379A1 (es) Inhibidor de triazolotiadiazola de la proteina quinasa c-met
BR112013032049A2 (pt) inibidores do vírus da hepatite c

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.